SSY Group Limited

2005

KYG8406X1034

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:10 2024-05-21 am EDT			5-day change	1st Jan Change
4.7 ^HKD	-1.05%		-4.47%	-4.86%

12:58pm	SSY Group Gets Production and Registration Approval for Parkinson’s Disease Drug in China	MT
May. 13	SSY Group’s Multiple Electrolytes Injection Passes Chinese Regulator’s Consistency Evaluation	MT

Lijun International Pharmaceutical Co., Ltd. Announces Resignation of Mr. Wu Qin as an Executive Director and Chairman of the Board

June 08, 2014 at 06:35 pm EDT

Lijun International Pharmaceutical (Holding) Co. Ltd. announced that Mr. Wu Qin has resigned as an executive director and chairman of the board of the company with effect from 4 June 2014.

Latest news about SSY Group Limited

SSY Group Gets Production and Registration Approval for Parkinson’s Disease Drug in China	06:58am	MT
SSY Group’s Multiple Electrolytes Injection Passes Chinese Regulator’s Consistency Evaluation	May. 13	MT
SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	Apr. 23	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension	Apr. 23	CI
SSY Group Logs Nearly 15% Boost in Q1 Profit	Apr. 16	MT
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	Apr. 08	MT
SSY Group Limited Announces Update on Product Development	Apr. 08	CI
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	Apr. 03	MT
SSY Group Limited Provides Update on Product Development	Apr. 03	CI
SSY Group's Profit Jumps 17% in 2023	Mar. 27	MT
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	Mar. 27	CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
SSY Group Obtains Drug Administration Approval for Diabetes Drug	Mar. 25	MT
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	Mar. 20	MT
SSY Group Limited Announces Update on Product Development	Mar. 20	CI
SSY Group Gets Bulk Drug Approval from Chinese Authorities	Mar. 01	MT
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	Mar. 01	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	Feb. 29	CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	Feb. 29	CI
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	Feb. 27	MT
SSY Group Limited Receives Approval for Gliclazide Tablet	Feb. 27	CI
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	Feb. 23	MT
SSY Group Limited Provides Update on Product Development	Feb. 22	CI
SSY Group’s Anesthetic Drug Granted Production, Registration Approval in China	Feb. 19	MT
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China	Feb. 18	CI

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for SSY Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.85 HKD

Average target price

6.227 HKD

Spread / Average Target

+28.38%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SSY GROUP LIMITED	-4.86%	1.85B
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+30.80%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+15.78%	238B
ROCHE HOLDING AG	-3.48%	210B
NOVARTIS AG	+10.50%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals

SSY Group Limited

Equities

2005

KYG8406X1034

Pharmaceuticals

Lijun International Pharmaceutical Co., Ltd. Announces Resignation of Mr. Wu Qin as an Executive Director and Chairman of the Board

Latest news about SSY Group Limited

Chart SSY Group Limited

Company Profile

Income Statement Evolution

Ratings for SSY Group Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals